Applied Pharmaceutical Science to Start US Trial of 2nd Gen RET Inhibitor
publication date: Jan 24, 2022
Applied Pharmaceutical Science has been approved to start US trials of its next-gen selective RET inhibitor, a proposed therapy for solid tumor RET cancers. APS, a Beijing-Philadelphia company, is a precision therapy cancer biotech that develops cancer therapies based on cancer genetics, protein structure/function, synthetic medicinal chemistry, and verification via experiment and computation. The trial will enroll solid tumor patients with RET gene alterations or resistance to first-gen RET inhibitors. In Q2, APS plans to file an IND in China for the RET inhibitor and start a global trial. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.